Literature DB >> 9603126

Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis.

A U Wells1, D M Hansell, P L Haslam, M B Rubens, J Cailes, C M Black, R M du Bois.   

Abstract

Lone cryptogenic fibrosing alveolitis (CFA) is histologically identical to fibrosing alveolitis associated with systemic sclerosis (FASSc), but it has a much worse prognosis after matching for disease severity at presentation. The aims of this study were to gain insights into possible pathogenetic mechanisms contributing to this prognostic difference, by comparing bronchoalveolar lavage (BAL) cellularity in the two diseases, and to evaluate the relationships between BAL findings and the regional and global extent of disease, quantified by thin-section computed tomography (CT) and lung function indices. Patients with CFA were distinguished by more extensive fibrosing alveolitis on CT (p < 0.02) and by higher counts of neutrophils (total per ml, p < 0.02; percentage p < 0.03) and eosinophils (total per ml, p < 0.002; percentages, p < 0.02) in BAL fluid. After adjustment for functional and morphologic measures of disease extent, eosinophil percentages and total counts were increased in CFA (p < 0.05 in all 12 multivariate models), but they were not independently related to regional or global disease severity. Neutrophil percentages and total counts were virtually identical in CFA and FASSc in disease of comparable severity, and they increased with increasingly extensive lobar disease and global disease, as judged by CT, p < 0.0005 in all analyses. Neutrophil levels were more closely linked to the extent of disease on CT than to the severity of functional impairment, on univariate and multivariate analysis. The higher BAL eosinophil levels seen in CFA, compared with those seen in FASSc, after adjustment for disease extent, indicate that an eosinophilic influx may be linked to the pathogenesis of fibrosing alveolitis. By contrast, BAL neutrophil levels increase with increasingly extensive disease on CT, but they do not differ independently between CFA and FASSc, suggesting that neutrophil degradation products are unlikely to account for the excess mortality in CFA, compared with that in FASSc.

Entities:  

Mesh:

Year:  1998        PMID: 9603126     DOI: 10.1164/ajrccm.157.5.9609096

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  14 in total

Review 1.  Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis.

Authors:  A Wells
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Interstitial lung disease in systemic sclerosis: current and future treatment.

Authors:  Roberto Giacomelli; Vasiliki Liakouli; Onorina Berardicurti; Piero Ruscitti; Paola Di Benedetto; Francesco Carubbi; Giuliana Guggino; Salvatore Di Bartolomeo; Francesco Ciccia; Giovanni Triolo; Paola Cipriani
Journal:  Rheumatol Int       Date:  2017-01-06       Impact factor: 2.631

4.  Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.

Authors:  Stefania Volpinari; Renato La Corte; Stefano Bighi; Franco Ravenna; Napoleone Prandini; Andrea Lo Monaco; Francesco Trotta
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

5.  Granulocyte-colony stimulating factor levels in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis.

Authors:  J Ashitani; H Mukae; H Taniguchi; T Ihi; J Kadota; S Kohno; S Matsukura
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

6.  Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis.

Authors:  M R Hussein; H I Hassan; E R M Hofny; M Elkholy; N A Fatehy; A E A Abd Elmoniem; A M Ezz El-Din; O A Afifi; H G Rashed
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

Review 7.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

Review 8.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

9.  Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis.

Authors:  H Mukae; H Iiboshi; M Nakazato; T Hiratsuka; M Tokojima; K Abe; J Ashitani; J Kadota; S Matsukura; S Kohno
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

10.  Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.

Authors:  Charlie Strange; Marcy B Bolster; Michael D Roth; Richard M Silver; Arthur Theodore; Jonathan Goldin; Philip Clements; Joanie Chung; Robert M Elashoff; Robert Suh; Edwin A Smith; Daniel E Furst; Donald P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.